The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg

According to the EAACI/GA(2)LEN/EDF guidelines for urticaria management, modern non-sedating H1-antihistamines are the first-line symptomatic treatment for chronic urticaria. Two previous randomized clinical trials demonstrated rupatadine efficacy and safety in chronic urticaria treatment. However,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the European Academy of Dermatology and Venereology 2009-09, Vol.23 (9), p.1088-1091
Hauptverfasser:	Giménez-Arnau, A, Izquierdo, I, Maurer, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Chronic Disease chronic urticaria Cyproheptadine - analogs & derivatives Cyproheptadine - therapeutic use Dose-Response Relationship, Drug Female Health Surveys Histamine H1 Antagonists, Non-Sedating - therapeutic use Humans Logistic Models Male Middle Aged non-sedating H1-antihistamines responder analyses rupatadine Severity of Illness Index Treatment Outcome Urticaria - drug therapy Urticaria - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!